Psychiatrists’ approach to vascular risk assessment in Latin America

Pablo Richly, Pablo López, Ezequiel Gleichgerrcht, Daniel Flichtentrei, María Prats, Ricardo Mastandueno, Julián Bustin, Marcelo Cetkovich-Bakmas

Pablo Richly, Pablo López, Ezequiel Gleichgerrcht, Julián Bustin, Marcelo Cetkovich-Bakmas, INECO (Institute of Cognitive Neurology), Buenos Aires C1126AA, Argentina
Pablo Richly, Pablo López, Ezequiel Gleichgerrcht, Julián Bustin, Marcelo Cetkovich-Bakmas, Institute of Neurosciences, Favaloro University, Buenos Aires C1093AA, Argentina
Pablo Richly, Marcelo Cetkovich-Bakmas, UDP-INECO Foundation, Diego Portales University, Santiago de Chile 8370076, Chile
Daniel Flichtentrei, María Prats, Ricardo Mastandueno, Intramed, Buenos Aires B1636AJK, Argentina

Author contributions: Richly P, Bustin J and Cetkovich-Bakmas M designed the study; Flichtentrei D, Prats M and Mastandueno R provided substantial contributions to acquisition of data; López P and Gleichgerrcht E provided substantial contributions to analysis and interpretation of data; Richly P and López P wrote the manuscript.

Correspondence to: Pablo Richly, MD, Head of Memory Clinic, INECO (Institute of Cognitive Neurology), Pacheco de Melo 1854, Buenos Aires C1126AA, Argentina. prichly@ineco.org.ar

Telephone: +54-11-48120010 Fax: +54-11-48120010
Received: April 15, 2014 Revised: July 16, 2014
Accepted: August 27, 2014
Published online: September 22, 2014

Abstract

AIM: To explore the way in which Latin American psychiatrists approach the screening of vascular risk factors in patients receiving antipsychotic medication.

METHODS: This was a descriptive, cross sectional study that surveyed Latin-American physicians to evaluate differences between groups divided in three main sections. The first section included demographic and professional data. The second section asked about the available medical resources: weighing scales, sphygmomanometer and measuring tape. Finally, the third section aimed at looking into the attitudes towards cardiovascular prevention. The latter was also divided into two subsections. In the first one, the questions were about weight, blood pressure and waist perimeter. In the second subsection the questions asked about the proportion of patients: (1) that suffered from overweight and/or obesity; (2) whose lipids and glycemia were controlled by the physician; (3) that were questioned by, and received information from the physician about smoking; and (4) that received recommendations from the physician to engage in regular physical activity. The participants were physicians, users of the medical website Intramed. The visitors were recruited by a banner that invited them to voluntarily access an online self-reported structured questionnaire with multiple options.

RESULTS: We surveyed 1185 general physicians and 792 psychiatrists. Regarding basic medical resources, a significantly higher proportion of general physicians claimed to have weighing scales ($\chi^2 = 404.9; P < 0.001$), sphygmomanometers ($\chi^2 = 419.3; P < 0.001$), and measuring tapes ($\chi^2 = 336.5; P < 0.001$). While general physicians measured overweight and metabolic indexes in the general population in a higher proportion than in patients treated with antipsychotics ($Z = -11.91; P < 0.001$), psychiatrists claimed to measure them in patients medicated with antipsychotics in a higher proportion than in the general population ($Z = -3.26; P < 0.001$). Also general physicians tended to evaluate smoking habits in the general population more ($Z = -7.02; P < 0.001$), but psychiatrists evaluated smoking habits in patients medicated with antipsychotics in a higher proportion than in the general population ($Z = -3.19; P < 0.001$). While general physicians measured overweight and metabolic indexes in the general population in a higher proportion than in patients treated with antipsychotics ($Z = -11.91; P < 0.001$), psychiatrists claimed to measure them in patients medicated with antipsychotics in a higher proportion than in the general population ($Z = -3.26; P < 0.001$). Also general physicians tended to evaluate smoking habits in the general population more than psychiatrists ($Z = -7.02; P < 0.001$), but psychiatrists evaluated smoking habits in patients medicated with antipsychotics more than general physicians did ($Z = -2.25; P = 0.024$). General physicians showed a significantly higher tendency to control blood pressure ($\chi^2 = 334.987; P < 0.001$), weight ($\chi^2 = 435.636; P < 0.001$) and waist perimeter ($\chi^2 = 96.52; P < 0.001$) themselves and they did so in all patients. General physicians suggested physical activity to all patients more...
frequently ($Z = -2.23; P = 0.026$), but psychiatrists recommended physical activity to patients medicated with antipsychotics more frequently ($Z = -7.53; P < 0.001$).

**CONCLUSION:** Psychiatrists usually check vascular risk factors in their patients, especially in those taking antipsychotics. General practitioners check them routinely without paying special attention to this population.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Antipsychotics; Metabolic syndrome; Psychiatric patients; Schizophrenia; Vascular risk factors

**Core tip:** This is a descriptive, cross sectional study that surveyed Latin-American physicians to explore the way in which Latin-American psychiatrists approach the screening of vascular risk factors in patients receiving antipsychotic medication. We surveyed 1185 general physicians and 792 psychiatrists. We found that psychiatrists usually check vascular risk factors in their patients, especially those taking antipsychotics. General practitioners check them routinely without paying special attention to this population.

Richly P, López P, Gleichgerrech E, Flichtentrei D, Prats M, Mastandueno R, Bustin J, Cetkovich-Bakmas M. Psychiatrists’ approach to vascular risk assessment in Latin America. *World J Psychiat* 2014; 4(3): 56-61 Available from: URL: http://www.wjgnet.com/2220-3206/full/v4/i3/56.htm DOI: http://dx.doi.org/10.5498/wjp.v4.i3.56

**INTRODUCTION**

Heart attack and stroke are the two leading causes of disability and mortality worldwide[11]. Tackling vascular risk factors such as high blood pressure, cholesterol, overweight/obesity, tobacco use, lack of physical activity, and hyperglycemia, among others, is the most efficient strategy to prevent vascular disease[12]. In fact, the presence of at least two of these risk factors is associated with the well-established metabolic syndrome, a disorder characterized by a constellation of risks that appear to have a common physiopathology leading to markedly increased cardiovascular risk[13]. Because these factors can be controlled, treated or modified, their early detection is crucial among younger patients, thus enabling early intervention[14].

The combination of two or more of these risk factors can be considered metabolic syndrome due to the risk increase that the combination generates, together with the hypothesis that they share a common physiopathology[13].

The use of antipsychotics has been linked with the development of metabolic syndrome, especially in younger patients[5,6]. Frequently, patients diagnosed with schizophrenia are prescribed antipsychotic medication for long periods of time. They are a particularly vulnerable population because schizophrenia itself is linked to an increased burden of cardiovascular disease[7,9]. In fact, cardiovascular causes of death are about twice as common in patients suffering from schizophrenia as they are in the general population, with a peak relative risk in early life. Certain risk factors such as weight, smoking, diet and activity levels appear to have a critical role in this phenomenon[9]. However, physicians don’t usually take this into account, neither before prescribing antipsychotics nor during treatment[9].

This issue becomes a priority since detection of high risk population may lead to a more thorough evaluation and early treatment of the vascular disease[10]. Although most of the epidemiological data comes from European and North American populations, some studies have preliminarily shown that comparable trends occur in developing countries[11]. For this reason, understanding the way in which physicians approach the issue of screening for vascular risk factors in patients receiving antipsychotic medication is important in order to design better training strategies that will ultimately translate into more efficient patient care. The present study sought to explore this issue.

**MATERIALS AND METHODS**

**Study design**

This study was descriptive, cross-sectional with a control group.

**Potential participants**

Potential participants were licensed physicians registered as psychiatrists or general physicians who were users of Intramed (www.intramed.net), an online portal for health professionals. Visitors were recruited by a banner that invited them to voluntarily access an online questionnaire. All participants gave their informed consent by clicking an “I agree” button placed beneath an explanatory letter. Potential respondents were informed of the anonymity of their responses, which was achieved by deleting their names and email addresses from the database.

**Questionnaire**

The questionnaire was designed by researchers from INECO (Institute of Cognitive Neurology, Buenos Aires) together with researchers from Intramed. It consisted of a self-reported structured questionnaire with multiple options. It was divided into three main sections: demographic/professional profile, availability of basic medical resources, and attitudes towards cardiovascular prevention.

The first section gathered basic demographic and professional data. The second section asked about participants’ access to basic medical resources in their workplaces, namely: weighing scales, sphygmomanometer, and measuring tape. We picked these items in particular because of their relevance in obtaining objective measures directly associated with risk factors for metabolic syndrome.
The third section asked about participants’ attitudes towards cardiovascular prevention, and was divided into two subsections. In the first one, questions were about weight, blood pressure, and waist perimeter. We asked whether physicians measured these variables, the way in which they did it, and in which patients (i.e., all patients or those that received anti-psychotic medication). In the second subsection, we asked about the proportion of patients seen by participants in their daily practice: (1) that suffered from overweight and/or obesity; (2) whose lipid levels and glycemia were controlled by the physician; (3) that have been questioned by, and received information from the physician about smoking; and (4) that were recommended by the physician to engage in regular physical activity.

**Statistical analysis**

All statistical analyses were conducted using the IBM-SPSS 19.0 package. When inferential hypotheses were tested on categorical data, Pearson $\chi^2$ tests were calculated in order to evaluate differences across groups. Comparisons between groups on ordinal measurements were conducted using independent Mann-Whitney $U$ test. Due to the large sample size of the present study and the fact that, in this case, the value of $U$ approaches a normal distribution, the null hypothesis has been tested by a $Z$-test to facilitate the comprehension of the analysis.

**RESULTS**

A total of 1977 Latin-American physicians completed the survey. The sample consisted of 1185 general practitioners (544 female and 641 male; age = 47.04) and 792 psychiatrists (440 female and 352 male, age = 48.92). There was a significant difference in the proportion of participants from each gender between both specialties ($\chi^2 = 17.677, P < 0.001$).

Regarding access to measurement instruments, a significantly higher proportion of general physicians claimed to have weighing scales ($\chi^2 = 404.9; P < 0.001$), sphygmomanometers ($\chi^2 = 419.3; P < 0.001$), and measuring tapes ($\chi^2 = 336.5; P < 0.001$) at their practice sites (Table 1).

Regarding routine measurement of overweight and metabolic indexes, psychiatrists claimed to measure these variables in patients medicated with antipsychotics (AP) in a significantly higher proportion than in the general population ($Z = -3.26; P < 0.001$). On the other hand, general physicians answered that they measured overweight and metabolic indexes in the general population in a higher proportion than in patients treated with AP ($Z = -11.91; P < 0.001$) (Figures 1 and 2).

In regards to the assessment of tobacco use, general physicians tended to evaluate smoking habits in the general population more than psychiatrists ($Z = -7.02; P < 0.001$), but these evaluated smoking habits in patients medicated with AP more than general physicians did ($Z = -2.25; P = 0.024$) (Figure 3).
General physicians showed a significantly higher tendency to control blood pressure than psychiatrists ($\chi^2 = 334.987; P < 0.001$). They also tended to differ in how, and in which patients, they did this, because they primarily measured it themselves ($\chi^2 = 641.785; P < 0.001$) and they controlled it mostly in all patients ($\chi^2 = 162.092; P < 0.001$) (Table 2).

In addition to this, significant differences existed in regards to the recommendation by general physicians and psychiatrists as to physical activity. General physicians recommended physical activity to all patients more frequently ($Z = -2.23; P = 0.026$). On the other hand, psychiatrists recommended physical activity to patients medicated with AP more frequently ($Z = -7.53; P < 0.001$) (Figure 4).

Even though all respondents claimed they controlled weight (Table 2), we found significant differences between the way in which it was controlled, and in which patients it was controlled. General physicians, in a higher proportion, controlled weight themselves ($\chi^2 = 435.636; P < 0.001$) and they did so in all patients ($\chi^2 = 251.214; P < 0.001$).

Additionally, a significant difference can be observed between general physicians and psychiatrists in the control of the patients’ waist perimeter (Table 2), in how it was done, and in which patients it was controlled. General physicians, in a higher proportion, controlled waist perimeter ($\chi^2 = 96.52; P < 0.001$) and they also, in a higher proportion, did so themselves ($\chi^2 = 211.308; P < 0.001$). They tended to control waist perimeter more frequently in all patients ($\chi^2 = 119.17; P < 0.001$).

**DISCUSSION**

As can be seen in the results, most psychiatrists are aware of the importance of taking into account vascular risk factors. Psychiatrists claim that they usually check them in their patients, especially in those taking antipsychotics. Despite controlling vascular risk factors in their patients, psychiatrists tend to refer them to general practitioners instead of handling this issue themselves.

As expected, general practitioners routinely check vascular risk factors in all their patients. However, they don’t pay special attention to patients taking antipsychotics, even though these medications increase the risk of developing cardiovascular disease.

A limitation of this study is that data was gathered through a self-reported questionnaire which, as was previously suggested, has a tendency of overestimating performance of respondents[12]. Also, the use of an online questionnaire, instead of an interview, represents a limitation of the data quality.

Finally, even though doctors seem to be more aware of the importance of cardiovascular burden in psychiatric patients, there still is a lot of work to do in this regard, since epidemiological studies show the paucity of actual monitoring of vascular risk factors in patients taking anti-
psychotics\textsuperscript{13}. Yet, not only screening of vascular risk factors in this population is lacking, but also treatment when detected\textsuperscript{14}. A deeper integration of psychiatric and physical health care systems for patients with mental disorders is urgently needed.

**REFERENCES**

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Colleng LE, Colan SD, Colquhoun S, Colson KE, Connolly J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vacoano KC, Couser W, Cowie BC, Criqui MH, Cross M, Dahdahkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola EP, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Franssen M, Friedman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hayes RJ, Hoorn E, Hotze PJ, Hoyer D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kromhout D, Kucreload K, Kuper H, Lartey A, Lim SS, Li JS, Loffing J, Lozano R, Loo YG, Lonn E, Masicheva N, Mathers C, Mathur R, Meng X, Menon R, Mensah GA, Michaud K, Miskovic D, Myers J, Naghavi M, Nallamothu BK, Nanchahal K, Narayan KM, Narwal R, Navarro D, Neves A, Nistor GI, Nonas C, Norrving B, Nor奕 C, O'Herlihy R, O'Sullivan CE, Onwujekwe EO, Osmond DE, Persaud K, Paterlini A, Pei Y, Perico N, Phillips D, Pierce K, Pope CA, Porritt R, Pournamini F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenberg LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, T eyjej IH, Towbin JA, Truelsen T, Undurraga EA, Venkatasesubramanian N, Vatrapu R, Vyas S, Wagner G, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wu L, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazrooa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2095-2128 [PMID: 23245604 DOI: 10.1016/S0140-6736(12)61728-0]

2. Mendis S, Fuchs P, Norrving B. Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization (in collaboration with the World Heart Federation and World Stroke Organization), Geneva, 2011

3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchtman JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009; 120: 1640-1645 [PMID: 19805654 DOI: 10.1161/CIRCULATIONAHA.109.192644]

4. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC, Hayman LL, Lloyd-Jones D, Pandey DK, Sanchez EJ, Schram AP, Whitsel LP. Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. *Circulation* 2011; 124: 967-990 [PMID: 21788592 DOI: 10.1161/CIR.0b013e3182285a81]

5. Mitchell AJ, Malone D. Physical health and schizophrenia. *Curr Opin Psychiatry* 2006; 19: 432-437 [PMID: 16721177]

6. Pramyothin P, Khaodhia L. Metabolic syndrome with the atypical antipsychotics. *Curr Opin Endocrinol Diabetes Obes* 2010; 17: 460-466 [PMID: 20717020 DOI: 10.1097/MED.0b013e32835de61c]

7. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. *J Clin Psychiatry* 2007; 68 Suppl 4: 4-7 [PMID: 17539693]

8. Ferreira L, Belo A, Abreu-Lima C. A case-control study of vascular risk factors and cardiovascular risk among patients with schizophrenia in a country in the low cardiovascular risk region of Europe. *Rev Port Cardiol* 2010; 29: 1481-1485 [PMID: 21265491]

9. Laundon W, Muzyk AJ, Gagliardi JP, Christopher EJ, Roether-Christian T, Jiang W. Prevalence of baseline lipid and metabolic syndrome in non-Euro-American societies. *J Cardiovasc Med* 2013; 14: 757-766 [PMID: 24338586 DOI: 10.2459/JCM.0b013e328362076a]

10. Bou Khallil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. *Clin Neuropsychopharmacol* 2012; 35: 141-147 [PMID: DOI: 10.1097/WNP.0b013e31824d5288]

11. Baxter P, Norman G. Self-assessment or self deception? A lack of association between nursing students’ self-assessment and performance. *J Adv Nurs* 2011; 67: 2406-2413 [PMID: 21517941 DOI: 10.1111/j.1365-2648.2011.05658]

12. Mitchell AJ, Delaflon F, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic
review and meta-analysis of screening practices. *Psychol Med* 2012; **42**: 125-147 [PMID: 21846426 DOI: 10.1017/S00332917110105X]

Steylen PM, van der Heijden FM, Kok HD, Sijben NA, Verhoeven WM. Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment. *Int J Psychiatry Clin Pract* 2013; **17**: 125-130 [PMID: 23437800 DOI: 10.3109/13651501.2013.779000]

P-Reviewer: Ciccone MM, Dumitrascu DL  S-Editor: Ji FF  L-Editor: A  E-Editor: Liu SQ
